β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases.

β-Aminoarteether (SM934;10 μM; 24 hours) treatment directly enhances IL-10 production and suppresses IL-12/23p40 production in primary peritoneal macrophages with IFN-γ stimulation[1]. In vitro, β-Aminoarteether (SM934) could suppress the Th1 and Th17 polarization, but exerted no influence on Treg differentiation[1].

β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β-Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice[1]. Animal Model: Female NZB/W F1 mice (Six and half months old)[1]Dosage: 1 mg/kg, 3 mg/kg, and 10 mg/kg Administration: Oral administration; daliy; for 3 months Result: Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.

133162-24-0

C17H29NO5

327.42

SM934 free base;β-Aminoarteether

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years